Verastem | VSTM - Ebit


Verastem reported $-44.9M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Alaunos Therapeutics USD -1.01M 175K Mar/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Curis USD -11.52M 3.64M Mar/2026
Cytokinetics USD -179.17M 2.05M Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Incyte USD -707.47M 1.41B Sep/2026
Laboratory Of America USD 418M 38.7M Sep/2026
Novartis USD 4.73B 549M Jun/2026
Pfizer USD -180M 5.16B Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
TG Therapeutics USD 21.67M 13.12M Jun/2026
Verastem USD -44.9M 3.42M Mar/2026